None
ATLANTA (AP) — The Atlanta Falcons are back in first place in the NFC South and again in control of their playoff hopes. Rookie quarterback Michael Penix Jr. showed the poise in his first NFL start the Falcons will need to take advantage of their opportunity to end a six-year playoff drought. Powered by a big-play defense that produced two pick-6s, a solid starting debut by Penix and two rushing touchdowns by Bijan Robinson, the Falcons cruised past the hapless New York Giants 34-7 on Sunday. On Sunday night, the Falcons (8-7) received the assist they needed when Tampa Bay lost at Dallas . Because the Falcons swept the Buccaneers, they hold the tiebreaker advantage if they remain tied atop the division. The Falcons have games remaining at Washington on Sunday night and at home against Carolina to close the regular season. If Atlanta wins both games, it would win the division and have a home playoff game. The Falcons are assured of their best record since a 10-6 finish under coach Dan Quinn in 2017, their most recent playoff season. Quinn is in his first season as Washington's coach and has led the Commanders (10-5) to three straight wins, including Sunday's 36-33 victory over Philadelphia. Penix, the No. 8 overall pick in this year's NFL draft, was promoted after coach Raheem Morris benched Kirk Cousins. Penix completed 18 of 27 passes for 202 yards with one interception on a pass that should have been caught by tight end Kyle Pitts. Penix is not a dual-threat quarterback, but he showed the ability to escape pressure in the pocket that Cousins lacks following his 2023 Achilles tendon injury. The left-hander's superior arm strength also was immediately obvious. What’s working Robinson's production provided a safety net for the offense which helped make for a smooth transition to Penix. Robinson had scoring runs of 2 and 4 yards. Robinson has rushed for 10 touchdowns this season. He's the first Atlanta player with 10 more more rushing touchdowns since Devonta Freeman during the 2016 Super Bowl season. Robinson ran for 94 yards on 22 carries and had 103 yards from scrimmage. His 11th game this season with at least 100 yards from scrimmage are the most for the Falcons since Warrick Dunn's 11 in 2005. Morris said Robinson deserves to be considered with Philadelphia's Saquon Barkley in discussions regarding the league's top running backs. “Bijan has been outstanding all year in the things that he’s able to do," Morris said. “He’s special. If it wasn’t for this other guy out in Philly, he’d get a lot more recognition across the league. But that guy is having a special year, and Bijan’s not far behind him.” What needs help With kicker Younghoe Koo on injured reserve and watching from the sideline, Riley Patterson was wide left on his first field-goal attempt from 43 yards. Patterson rebounded to make attempts from 52 and 37 yards. Stock up Jessie Bates III and Matthew Judon each had a pick-6 to highlight a day of big plays for the defense. Arnold Ebiketie had his fifth sack of the season and added a fumble recovery. Kaden Ellis added a strip-sack. He also has five sacks this season, including sacks in four consecutive games. It is the longest streak for Atlanta since Patrick Kerney had sacks in five straight games in 2001. Stock down There was some thought that a change at quarterback could be good news for Pitts, who often seemed to be missing in action with Cousins running the offense. After all, a tight end often is a natural target for quick passes from a rookie making his first start. Instead, Pitts had a poor start to the Penix era when he bobbled his first pass from the left-hander, creating an interception by cornerback Cor’Dale Flott. Pitts caught a 7-yard pass on his only other target. For the season, Pitts has 41 catches for 543 yards and three touchdowns. Injuries There will be much interest in this week's injury report after WR Drake London (hamstring) was hurt in the second half. Morris provided an optimistic postgame outlook on London. CB Antonio Hamilton (quad) did not return after leaving the game in the first half. Key number 8: Bates has four interceptions and four forced fumbles. His combined eight forced turnovers lead the NFL. Next steps The game against Jayden Daniels and the Commanders is a reminder Penix was only the fourth of six quarterbacks selected in the first round of the NFL draft. Daniels, from LSU, was the No. 2 overall pick behind Caleb Williams by Chicago. ___ AP NFL: https://apnews.com/hub/nfl Charles Odum, The Associated PressBRIDGEWATER, NEW JERSEY / ACCESSWIRE / December 6, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced it has entered into a securities purchase agreement to raise gross proceeds of approximately $2.02 million through a private placement. The agreement includes the issuance of 961,446 shares of common stock (or common stock equivalents) and warrants to purchase up to an additional 480,723 shares of common stock. Each share (or common stock equivalent) is priced at $2.10 and is accompanied by a warrant. The warrants will have an exercise price of $2.031 per share, becoming exercisable six months after issuance and expiring five and one-half years from the date of issuance. The closing of this transaction is expected on or about December 9, 2024, subject to customary closing conditions. Strategic Investors and Placement Details The financing was led by Gravitas Capital and SDS Capital Group, alongside other biotechnology-focused private investors. President Street Global served as the exclusive placement agent for the offering, ensuring seamless execution of the transaction. After deducting placement agent fees and other offering-related expenses, the Company intends to allocate the net proceeds toward clinical development, including advancing its flagship TH104 development program, as well as general working capital. Advancing Innovation in Biotechnology This financing reinforces Tharimmune's commitment to advancing its portfolio of therapeutic candidates. TH104, the Company's lead clinical asset, is designed to address chronic pruritus associated with primary biliary cholangitis (PBC), a rare and challenging autoimmune liver disease. Regulatory Details The securities in this private placement were offered under Section 4(a)(2) of the Securities Act of 1933, as amended, and Regulation D thereunder. The shares of common stock and underlying warrants are not registered under the Securities Act or state securities laws. The Company has agreed to file a resale registration statement covering these securities to enable their future trading upon registration or qualification under applicable laws. About Tharimmune Tharimmune, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies in immunology, inflammation, and oncology. The Company's lead product candidate, TH104, leverages a unique transdermal buccal film technology designed to address inflammatory conditions, including pruritus associated with PBC. Tharimmune is also advancing TH023, an oral TNF-alpha inhibitor, and exploring novel multi-specific biologics targeting solid tumors. Through a licensing agreement with OmniAb, Inc., the Company harnesses cutting-edge antibody discovery platforms to target specified disease markers. Learn more at www.tharimmune.com . Forward-Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this press release, including statements regarding the timing and design of Tharimmune's future Phase 2 trial, Tharimmune's strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "depends," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "target," "should," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Factors that may cause such differences, include, but are not limited to, those discussed under Risk Factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2023 and other periodic reports filed by the Company from time to time with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date of this release. Subsequent events and developments may cause the Company's views to change; however, the Company does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this release. Contact Information Tharimmune, Inc. ir@tharimmune.com Alliance Advisors IR Tirth T. Patel tpatel@allianceadvisors.com 212-201-6614 SOURCE: Tharimmune, Inc. View the original on accesswire.com
Pathfinder Bancorp, Inc. Declares DividendBurt, the huge crocodile that rose to fame with a cameo in the movie “Crocodile Dundee” and continued to impress visitors with his fiery temper and commanding presence, has died. Burt died over the weekend, the Crocosaurus Cove reptile aquarium in Darwin, Australia , said. He was at least 90 years old. “Known for his independent nature, Burt was a confirmed bachelor — an attitude he made clear during his earlier years at a crocodile farm,” Crocosaurus Cove wrote in social media posts. “He wasn’t just a crocodile, he was a force of nature and a reminder of the power and majesty of these incredible creatures. While his personality could be challenging, it was also what made him so memorable and beloved by those who worked with him and the thousands who visited him over the years,” the aquarium wrote. A saltwater crocodile , Burt was estimated to be more than 5 meters (16 feet) long. He was captured in the 1980s in the Reynolds River and became one of the most well-known crocodiles in the world, according to Crocosaurus Cove. The 1986 movie stars Paul Hogan as the rugged crocodile hunter Mick Dundee. In the movie, American Sue Charlton, played by actress Linda Kozlowski, goes to fill her canteen in a watering hole when she is attacked by a crocodile before being saved by Dundee. Burt is briefly shown lunging out of the water. But the creature shown in more detail as Dundee saves the day is apparently something else. The Internet Movie Database says the movie goofed by depicting an American alligator, which has a blunter snout. The Australian aquarium where Burt had lived since 2008 features a “Cage of Death” which it says is the nation's only crocodile dive. It said it planned to honor Burt's legacy with a commemorative sign “celebrating his extraordinary life and the stories and interactions he shared throughout his time at the park.”Today’s Love horoscope brings a mix of passion, deep connection, and the opportunity for growth across all zodiac signs. Whether you're in a relationship or single, the energy of the day encourages heartfelt conversations, meaningful gestures, and the chance to strengthen bonds. Some signs may experience intense emotions, while others find joy in simple, tender moments. Aries Passion runs high, but communication is crucial. Misunderstandings can arise if you rush into conclusions. Take time to express your feelings and listen to your partner. Singles may find a romantic connection through a shared interest or unexpected social setting. Taurus Patience is key this week as your partner may seem distant. Instead of pushing, offer quiet support. Singles might feel unsure about a potential connection, but trust your instincts. Love blooms when you focus on building a strong emotional foundation. Gemini Flirtation and fun are in the air. Whether single or attached, your charm is magnetic. Couples should embrace spontaneity to reignite sparks. Singles, a casual meeting could evolve into something meaningful. Stay open to surprises and let conversations flow naturally. Cancer Deep emotions surface, urging meaningful connections. Couples may have heart-to-heart conversations that strengthen bonds. Singles, a nostalgic memory might draw you to someone familiar. Let your nurturing side shine, but avoid overthinking small issues in budding relationships. Leo You crave attention and romance, but balance is vital. Couples should avoid taking their partner’s efforts for granted. Singles might attract someone who loves your confidence but craves authenticity. Embrace vulnerability to deepen emotional connections and let love flourish. Virgo Practicality blends with romance this week. Couples may discuss future plans that solidify their bond. Singles, you may meet someone through work or shared routines. Be mindful of overanalyzing new connections—sometimes, love thrives in the simplest of moments. Libra Your natural charm draws people closer, but indecision could hinder progress in love. Couples should prioritize fairness and compromise in arguments. Singles might attract multiple suitors, but clarity in your own desires is essential for building a genuine connection. Scorpio Intense emotions define your week. Couples may face power struggles, but honesty leads to healing. Singles might feel drawn to a mysterious person. Dive deep but tread carefully, ensuring your emotional needs align before committing fully. Sagittarius Freedom and connection coexist beautifully. Couples may plan an adventurous outing that revives their bond. Singles, someone with a lively spirit could captivate you. Trust your instincts, but don’t shy away from showing your softer side. Capricorn Commitment takes center stage this week. Couples may work through practical challenges together, strengthening their trust. Singles, a long-term prospect might emerge, but only if you’re willing to step outside your comfort zone. Let love grow at its own pace. Aquarius Unconventional approaches to love could bring joy. Couples might experiment with new activities that reignite excitement. Singles may attract someone through intellectual or unique interests. Keep communication open to avoid misunderstandings and let relationships evolve naturally. Pisces Romantic dreams feel closer to reality. Couples may share tender moments that deepen their bond. Singles, trust your intuition—it could guide you toward a soulful connection. Be cautious of overidealizing new relationships and focus on genuine compatibility. Get Latest News Live on Times Now along with Breaking News and Top Headlines from Astrology and around the world.
ByteDance is about to learn a painful genAI lessonWhile Cleveland heads into Sunday's home matchup with the reigning NBA champion Boston Celtics sporting the league's best record, the Cavaliers also come in trying to avoid a three-game losing streak. Cleveland had its 15-game winning streak to open the season interrupted in its last meeting with Boston, a 120-117 win for the host Celtics on Nov. 19. The Cavaliers recovered with a pair of wins over Toronto and New Orleans, but fell in meetings with the Atlanta Hawks on Wednesday and Friday. Javascript is required for you to be able to read premium content. Please enable it in your browser settings. Scenes from Georgia Tech at Georgia college football at Sanford Stadium in Athens on Nov. 29, 2024. (Photos: Dave Quick) Click for more. PHOTOS: Georgia Tech at Georgia Football
Simple Hacks to Make the Holidays Merrier (and Cheaper)TV personality Andre Rerekura captures snake on the plane
Burt, the huge crocodile that rose to fame with a cameo in the movie “Crocodile Dundee” and continued to impress visitors with his fiery temper and commanding presence, has died. Burt died over the weekend, the Crocosaurus Cove reptile aquarium in Darwin, Australia , said. He was at least 90 years old. “Known for his independent nature, Burt was a confirmed bachelor — an attitude he made clear during his earlier years at a crocodile farm,” Crocosaurus Cove wrote in social media posts. “He wasn’t just a crocodile, he was a force of nature and a reminder of the power and majesty of these incredible creatures. While his personality could be challenging, it was also what made him so memorable and beloved by those who worked with him and the thousands who visited him over the years,” the aquarium wrote. A saltwater crocodile , Burt was estimated to be more than 5 meters (16 feet) long. He was captured in the 1980s in the Reynolds River and became one of the most well-known crocodiles in the world, according to Crocosaurus Cove. The 1986 movie stars Paul Hogan as the rugged crocodile hunter Mick Dundee. In the movie, American Sue Charlton, played by actress Linda Kozlowski, goes to fill her canteen in a watering hole when she is attacked by a crocodile before being saved by Dundee. Burt is briefly shown lunging out of the water. But the creature shown in more detail as Dundee saves the day is apparently something else. The Internet Movie Database says the movie goofed by depicting an American alligator, which has a blunter snout. The Australian aquarium where Burt had lived since 2008 features a “Cage of Death” which it says is the nation's only crocodile dive. It said it planned to honor Burt's legacy with a commemorative sign “celebrating his extraordinary life and the stories and interactions he shared throughout his time at the park.”
Analysis Qualcomm's push into the PC arena is safe, at least for the moment, after a jury found its mobile processor designs had not violated Arm Holdings' licenses as the British chip designer had claimed. The decision came after five days of deliberations, marking the end of a more than two-year legal battle between Arm and one of its largest customers over allegations Qualcomm had breached the terms of its licenses when it acquired Nuvia back in 2021 for $1.4 billion. The jury decided in Qualcomm's favor with regard to two questions regarding the terms of its licenses with Arm: the case ultimately ended in a mistrial after the jury failed to resolve one of three questions set before them. Those questions boiled down to the following issues: The jury found in Qualcomm's favor on questions two and three, but was unable to reach consensus regarding whether Nuvia had breached its ALA with Arm. "We are pleased with today's decision. The jury has vindicated Qualcomm's right to innovate and affirmed that all the Qualcomm products at issue in the case are protected by Qualcomm's contract with ARM," Qualcomm said in a statement following the verdict. "We will continue to develop performance-leading, world-class products that benefit consumers worldwide, with our incredible Oryon ARM-compliant custom CPUs." These products include Qualcomm's Snapdragon X-Elite and X-Plus processors now found in a variety of AI PCs, as well as its Snapdragon 8 Elite smartphone chips. The designs were central to the case, with Arm arguing that the licenses granted to Nuvia to design an Arm-based server processor, couldn't be transferred to Qualcomm without its permission. However, the bigger issue related to Qualcomm's Nuvia-derived Oryon cores came down to how the royalty payments collected by Arm under the deal. Nuvia was apparently subject to a higher royalty rate than Qualcomm's mobile system on chip (SoC) designs. The issue came when Qualcomm attempted to use Nuvia's tech at that lower rate. The jury's findings regarding Qualcomm's actions mark a victory for the mobile chip giant's PC ambitions. Had the jury leaned in Arm's favor, the trial could have significantly impacted Qualcomm's PC push, sending it back to the drawing board on SoC designs or forcing it to renegotiate less favorable royalty rates with Arm. The latter could have resulted in more expensive products, making them less competitive with x86-based AI PCs from Intel and AMD. Introduced in May, Qualcomm's Snapdragon X-Elite and X-Plus, while not its first foray into the PC market, were among its most competitive, at the time boasting performance 2x higher in multithreaded workloads compared to Intel's 10-core Raptor Lake 1355U and 12-core 1360P processors. What's more, the chips were the first parts on the market to meet Microsoft's lofty 40 TOPS Copilot+ benchmark for AI PCs. Only chips with neural processing units capable of meeting this bar would get access to Microsoft's growing number of local AI features, including its controversial Recall feature. However, the exclusive nature of Qualcomm's X-series chips was rather short lived. Within months of the X-Elite's launch, both AMD and Intel introduced powerful new SoCs of their own, with NPUs qualifying them for the Copilot+ PC brand. This put Qualcomm in a vulnerable market position, with the future of these chips in the jury's hands. Arm had already made moves to derail Qualcomm's Oryon-based chips. In October, Arm reportedly moved to cancel Qualcomm's architecture licenses in an apparent bid to stall its latest generation of products based on those designs. While it seems Qualcomm's custom core designs are safe for now, with only two of three questions decided, the story isn't over yet. "We are disappointed that the jury was unable to reach consensus across the claims. We intend to seek a retrial due to the jury's deadlock," the chip designer said in a statement, received by El Reg following the conclusion of the trial. "From the outset, our top priority has been to protect Arm's IP and the unparalleled ecosystem we have built with our valued partners over more than 30 years. As always, we are committed to fostering innovation in our rapidly evolving market and serving our partners while advancing the future of computing." The fact is that Qualcomm, one of Arm's largest customers, is still heavily dependent on the IP house's technology. As such, finding an equitable resolution is in both party's long term interests. Further complicating the matter, Qualcomm's success in competing with Intel and AMD in the PC is a double-edged sword for Arm. For better or worse, Qualcomm's X-chips serve as Arm's ambassador to the AI PC space and show the architecture is viable in more than mobile and server applications. On the other hand, Qualcomm's X-series chips don't necessarily represent the best Arm has to offer. The Oryon core is based on an older ARMv8 design, which lacks, among other things, AI centric features found in modern ARMv9 designs, like those used in Apple's M4 SoCs . Perhaps, the most concerning challenge for Arm and why it seems bent on retrying the case is the precedent it sets. If Qualcomm can get away with acquiring chip technologies from Nuvia without renegotiating architecture licenses, what's to stop someone else from doing the same? And so, while this chapter of the Arm vs. Qualcomm saga may be over, it seems the story is far from over. ®Best Bets, Odds for the Titans vs. Jaguars Game – Week 14
None
WASHINGTON — President-elect Donald Trump on Friday nominated Dr. Marty Makary to lead the Food and Drug Administration, selecting a surgeon and author who gained national attention for opposing vaccine mandates and some other public health measures during the COVID-19 pandemic. Makary, a professor at Johns Hopkins University, is the latest in a string of Trump nominees who have declared the U.S. health system “broken” and in need of a shakeup. In books and articles Makary has decried the overprescribing of drugs, the use of pesticides on foods and the undue influence of pharmaceutical and insurance companies over doctors and government regulators. He will need to be confirmed by the Republican-led Senate to take the post. Trump announced the nomination in a statement Friday night, saying Makary “will restore FDA to the gold standard of scientific research, and cut the bureaucratic red tape at the agency to make sure Americans get the medical cures and treatments they deserve.” Headquartered in the Maryland suburbs outside Washington, the 18,000 employees of the FDA are responsible for the safety and effectiveness of prescription drugs, vaccines and medical devices as well as a swath of other consumer goods, including food, cosmetics and vaping products. Altogether those products represent an estimated 20% of U.S. consumer spending annually, or $2.6 trillion. Get the latest political news stories, from local elections and legislation to reaction to national events. By clicking Sign up, you agree to our privacy policy . Makary gained prominence on Fox News and other conservative outlets for his contrarian views during the COVID-19 pandemic. He questioned the need for masking and, though not opposed to the COVID-19 vaccine, had concerns about vaccinations in young children. The Centers for Disease Control and Prevention estimated that COVID-19 vaccinations prevented more than 686,000 U.S. deaths in 2020 and 2021 alone. While children faced much lower rates of hospitalization and death from the virus, medical societies including the American Academy of Pediatrics concluded that vaccinations significantly reduced severe disease in the age group. Trained as a surgeon and cancer specialist, Makary was part of a vocal group of physicians calling for greater emphasis on herd immunity to stop the virus, or the idea that mass infections would quickly lead to population-level protection. In a February 2021 Wall Street Journal piece, he wrote that “COVID will be mostly gone by April, allowing Americans to resume normal life.” That summer the delta variant of the virus ripped through the U.S., followed by omicron in the winter, leading to hundreds of thousands of additional deaths. If confirmed, Makary would be expected to report to anti-vaccine activist Robert F. Kennedy Jr., Trump's pick to oversee the nation’s Department of Health and Human Services, which includes the FDA. Makary does not share Kennedy’s discredited views on vaccines, but he has a similar distrust of the pharmaceutical industry. Makary has lamented how drugmakers used misleading data to urge doctors to prescribe OxyContin and other opioids as low-risk, non-addictive pain relievers. That marketing was permitted under FDA-approved labeling from the 1990s, suggesting the drugs were safe for common ailments like back pain. In more recent years, the FDA has come under fire for approving drugs for Alzheimer's, ALS and other conditions based on incomplete data that failed to show meaningful benefits for patients. A push toward greater scrutiny of drug safety and effectiveness would be a major reversal at FDA, which for decades has focused on speedier drug approvals. That trend has been fueled by industry lobbying and fees paid by drugmakers to help the FDA hire additional reviewers. Kennedy has proposed ending those payments, which would require billions in new funding from the federal budget. Other administration priorities would likely run into similar roadblocks. For instance, Kennedy wants to bar drugmakers from advertising on TV, a multibillion-dollar market that supports many TV and cable networks. The Supreme Court and other conservative judges would likely overturn such a ban on First Amendment grounds that protect commercial speech, experts note. Makary would also inherit a raft of ongoing projects at the FDA kicked off by outgoing Commissioner Robert Califf, including the reorganization of the agency's food division and plans to regulate artificial intelligence in medical technology. In the event of other controversial initiatives under Trump, career staffers may simply drag the work out until a new administration comes to power. “The bureaucracy can wait anybody out, and that’s an attitude I think you’ll hear a lot,” said Wayne Pines, a former FDA official under Republican and Democratic administrations.None